C. Neslusan

946 total citations
58 papers, 753 citations indexed

About

C. Neslusan is a scholar working on Endocrinology, Diabetes and Metabolism, Economics and Econometrics and Family Practice. According to data from OpenAlex, C. Neslusan has authored 58 papers receiving a total of 753 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Economics and Econometrics and 8 papers in Family Practice. Recurrent topics in C. Neslusan's work include Diabetes Treatment and Management (31 papers), Health Systems, Economic Evaluations, Quality of Life (16 papers) and Diabetes Management and Research (12 papers). C. Neslusan is often cited by papers focused on Diabetes Treatment and Management (31 papers), Health Systems, Economic Evaluations, Quality of Life (16 papers) and Diabetes Management and Research (12 papers). C. Neslusan collaborates with scholars based in United States, Sweden and United Kingdom. C. Neslusan's co-authors include Jodi Crystal-Peters, William H. Crown, Michael Willis, Mark W. Smith, Fredric J. Cohen, Song Xue, Sally Wade, Robert W. Dubois, Anita Chawla and Pierre Johansen and has published in prestigious journals such as PLoS ONE, Diabetes Care and Diabetes.

In The Last Decade

C. Neslusan

54 papers receiving 707 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Neslusan United States	12	276	240	236	164	129	58	753
Michele Tari Italy	13	198 0.7×	54 0.2×	211 0.9×	73 0.4×	66 0.5×	26	615
Mark Aagren United States	17	71 0.3×	716 3.0×	32 0.1×	16 0.1×	69 0.5×	42	1.1k
K. Kiviranta Finland	9	1.4k 5.1×	40 0.2×	177 0.8×	1.3k 7.7×	24 0.2×	14	1.7k
Dinah Foer United States	13	167 0.6×	83 0.3×	49 0.2×	115 0.7×	22 0.2×	45	654
Michael Pollack United States	14	113 0.4×	177 0.7×	14 0.1×	173 1.1×	80 0.6×	45	634
Matthew Dahl Canada	14	88 0.3×	197 0.8×	30 0.1×	63 0.4×	35 0.3×	26	649
Samuel C. Somers United States	8	271 1.0×	33 0.1×	33 0.1×	199 1.2×	15 0.1×	10	848
Mark Holdbrook United States	14	121 0.4×	337 1.4×	17 0.1×	19 0.1×	15 0.1×	28	909
D Schröder-Bernhardi Germany	9	50 0.2×	103 0.4×	7 0.0×	31 0.2×	49 0.4×	19	442
Filip Mejza Poland	16	486 1.8×	13 0.1×	45 0.2×	402 2.5×	24 0.2×	31	852

Countries citing papers authored by C. Neslusan

Since Specialization

Citations

This map shows the geographic impact of C. Neslusan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Neslusan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Neslusan more than expected).

Fields of papers citing papers by C. Neslusan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Neslusan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Neslusan. The network helps show where C. Neslusan may publish in the future.

Co-authorship network of co-authors of C. Neslusan

This figure shows the co-authorship network connecting the top 25 collaborators of C. Neslusan. A scholar is included among the top collaborators of C. Neslusan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Neslusan. C. Neslusan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Neslusan, C., et al.. (2021). Characteristics of hospital encounters and associated economic burden of patients with major depressive disorder and acute suicidal ideation or behavior. Hospital Practice. 49(3). 176–183. 5 indexed citations

Snider, Julia Thornton, Jeffrey Sullivan, Michael K. Hansen, et al.. (2019). Lifetime benefits of early detection and treatment of diabetic kidney disease. PLoS ONE. 14(5). e0217487–e0217487. 31 indexed citations

Willis, Michael, et al.. (2018). A Review of the Costs of Lower Limb Amputations in Patients With Diabetes in the US. Value in Health. 21. S73–S73. 5 indexed citations

Neslusan, C., et al.. (2018). Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes Therapy. 9(2). 565–581. 17 indexed citations

Gupta, Vishal, et al.. (2018). Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. Value in Health Regional Issues. 18. 65–73. 5 indexed citations

Neslusan, C., et al.. (2016). Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.. PubMed. 23(2). e151–68. 16 indexed citations

Evans, Marc, et al.. (2016). The Cost of Glycaemic Target Achievement with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Metformin and Sulphonylurea (MET+SU) in the UK. Value in Health. 19(7). A669–A669. 1 indexed citations

Neslusan, C., et al.. (2015). Impact Of Weight-Related Utilities On The Cost-Effectiveness Of Canagliflozin (Cana) Versus Sitagliptin (Sita) As Third-Line Therapy In Type 2 Diabetes Mellitus (T2dm) In A Canadian Setting. Value in Health. 18(3). A62–A62. 2 indexed citations

Hemels, M., et al.. (2015). The Cost-Effectiveness Evaluation of Canagliflozin Versus Dapagliflozin In Patients with type 2 Diabetes Mellitus Inadequately Controlled On Metformin Monotherapy In Spain. Value in Health. 18(3). A61–A61. 4 indexed citations

10.

Taieb, V., et al.. (2015). A Network Meta-Analysis (NMA) to Assess the Longer-Term Relative Efficacy of Canagliflozin in Patients with Type 2 Diabetes Inadequately Controlled on Metformin. Value in Health. 18(7). A598–A598. 7 indexed citations

11.

Neslusan, C., et al.. (2015). The Cost-Effectiveness of Canagliflozin Versus Sitagliptin as Third-Line Therapy in Type 2 Diabetes Mellitus (T2dm) in a Canadian setting. Value in Health. 18(3). A61–A61. 1 indexed citations

12.

Diels, Joris & C. Neslusan. (2015). Comparative Persistency with Newer agents used to Treat Type 2 Diabetes (T2dm) In the united states: canagliflozin Versus Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors and Glucagon-Like Peptide-1 (Glp-1) agonists. Value in Health. 18(3). A68–A69. 6 indexed citations

13.

Neslusan, C., et al.. (2015). Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value in Health Regional Issues. 8. 8–19. 16 indexed citations

14.

Hemels, M., et al.. (2015). The Cost-Effectiveness of Canagliflozin (Cana) Versus Sitagliptin (Sita) as an add-on to Metformin or Metformin Plus Sulphonylurea In The Treatment of Type 2 Diabetes Mellitus In Spain. Value in Health. 18(3). A62–A62. 1 indexed citations

15.

Neslusan, C., et al.. (2015). Cost-Effectiveness of Canagliflozin (Cana) Versus Sitagliptin (Sita) As Add-On To Metformin Plus Sulfonylurea In Patients With Type 2 Diabetes Mellitus (T2dm) In Brazil. Value in Health. 18(7). A864–A864. 3 indexed citations

16.

Neslusan, C., et al.. (2014). The association of health-related quality of life (HRQOL) and achievement of disease management goals in the treatment of type 2 diabetes mellitus (T2DM). Value in Health. 17(3). A257–A257. 1 indexed citations

17.

Schroeder, M., et al.. (2014). The Cost-Effectiveness OF Canagliflozin (Cana) Versus Dapagliflozin (Dapa) In Patients With Type 2 Diabetes Mellitus (T2dm) With Inadequate Control On Metformin (Met) Monotherapy In The United Kingdom. Value in Health. 17(7). A344–A344. 5 indexed citations

18.

Bacon, Tamar, et al.. (2014). The Cost-Effectiveness of Canagliflozin Verse Insulin-Secretagogues (Sulphonylureas) or Insulin In Patients With Type 2 Diabetes Mellitus (T2dm) As An Add-On To Metformin In Ireland. Value in Health. 17(7). A346–A346. 2 indexed citations

19.

Pacou, Maud, V. Taieb, Keith R. Abrams, et al.. (2013). Bayesian Network Meta-Analysis to Assess Relative Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin. Value in Health. 16(7). A609–A609. 8 indexed citations

20.

Treglia, Michael, C. Neslusan, & Rodney L. Dunn. (1999). Fluoxetine and dothiepin therapy in primary care and health resource utilization: Evidence from the United Kingdom. International Journal of Psychiatry in Clinical Practice. 3(1). 23–30. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact